研究者詳細 - 井山　諭

論文 - 井山　諭

分割表示 148 件中 101 - 120 件目／全件表示 >>

[An advanced metastatic breast cancer patient successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy].

Sato Y, Takayama T, Sagawa T, Sato T, Okamoto K, Takahashi S, Abe S, Iyama S, Murase K, Kato J, Niitsu Y

Gan to kagaku ryoho. Cancer & chemotherapy ( 3 ) 35 471 - 473 2008年03月 [査読有り]

PubMed

Successful treatment of chronic myeloproliferative disease-unclassifiable (CMPD-U) with no chromosomal abnormalities by imatinib mesylate

Satoshi Iyama, Takuya Matsunaga, Tsutomu Sato, Kazuyuki Murase, Naoko Araki, Rishu Takimoto, Masayoshi Kobune, Tamotsu Sagawa, Tetsuji Takayama, Yoshiro Niitsu

INTERNAL MEDICINE ( JAPAN SOC INTERNAL MEDICINE ) 47 ( 8 ) 791 - 794 2008年 [査読有り]

We report a chronic myeloproliferative disease-unclassifiable (CMPD-U) patient who achieved hematological remission following imatinib mesylate (imatinib). Chromosomal and molecular analyses demonstrated no genetic abnormalities of c-abl, bcr-abl, c-kit or platelet-derived growth factor receptor (PDGFR) genes from hematopoietic cells. Although there has been one report of CMPD-U patient with chromosomal abnormalities of the PDGFR gene having complete hematologic responses upon treatment with imatinib, there have not been similar reports of patients without chromosomal abnormalities. This is the first case report of a CMPD-U patient with no chromosomal abnormalities who completely responded to treatment with imatinib.

DOI PubMed

Successful treatment of autoimmune pancreatitis complicated with autoimmune thrombocytopenia and interstitial pneumonia by prednisolone

Kazuyuki Murase, Takuya Matsunaga, Tsuyoshi Hayashi, Hirotoshi Ishiwatari, Naoko Araki, Satoshi Iyama, Tsutomu Sato, Masayoshi Kobune, Rishu Takimoto, Koji Miyanishi, Toru Miyazaki, Hisami Ikeda, Junji Kato, Yoshiro Niitsu

INTERNAL MEDICINE ( JAPAN SOC INTERNAL MEDICINE ) 47 ( 11 ) 1033 - 1038 2008年 [査読有り]

DOI PubMed

[Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6].

Sagawa T, Sato Y, Takayama T, Kuroda H, Hirakawa M, Abe S, Iyama S, Sakamaki S, Kato J, Niitsu Y

Gan to kagaku ryoho. Cancer & chemotherapy ( 9 ) 34 1467 - 1471 2007年09月 [査読有り]

PubMed

[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].

Tamotsu Sagawa, Yasushi Sato, Tetsuji Takayama, Masahiro Hirakawa, Seiichiro Abe, Satoshi Iyama, Koji Miyanishi, Yutaka Kawano, Kohichi Takada, Tokiko Nakamura, Junji Kato, Yoshiro Niitsu

Gan to kagaku ryoho. Cancer & chemotherapy ( 9 ) 34 ( 9 ) 1481 - 4 2007年09月 [査読有り] [国内誌]

A 70-year-old man was admitted for tranverse colon cancer with multiple liver metastases. Hepatic arterial infusion chemotherapy and systemic chemotherapy (FOLFOX 4) were conducted postoperatively. Thirteen months after the first surgery, liver metastases became resectable and hepatectomy was performed. Though multiple liver metastases were unresectable at the time of the first examination, hepatectomy was possible followed by hepatic arterial infusion chemotherapy and systemic chemotherapy.

PubMed

[Reactivation of hepatitis B virus due to rituximab plus CHOP after preemptive lamivudine administration in a patient with diffuse large B-cell lymphoma].

Kaoru Ono, Satoshi Iyama, Takuya Matsunaga, Tsutomu Sato, Yasushi Sato, Toshinori Okuda, Kohichi Takada, Yutaka Kawano, Tsuyoshi Hayashi, Koji Miyanishi, Tamotsu Sagawa, Masayoshi Kobune, Rishu Takimoto, Junji Kato, Yoshiro Niitsu

Gan to kagaku ryoho. Cancer & chemotherapy ( 9 ) 34 ( 9 ) 1509 - 12 2007年09月 [査読有り] [国内誌]

A 59-year-old woman received eight cycles of R-CHOP for diffuse large B-cell lymphoma from July, 2004. Pretreatment HBV serological tests were positive, however, the transaminases were within normal limits, and she remained asymptomatic. Lamivudine (LAM) was administered orally from the start of R-CHOP. HBV-DNA levels gradually decreased and were not detected until December, 2004. LAM was administered until 3 months after the end of chemotherapy, with the entire treatment lasting less than 1 year. Two months after the cessation of treatment, she was re-admitted for general malaise. A liver function test revealed severe abnormalities, and HBVDNA levels were increased. Clinically, she was experiencing acute hepatitis due to HBV reactivation. She was then treated with LAM and interferon-beta immediately. Her HBV-DNA levels soon decreased, and liver function improved.

PubMed

骨髄腫から産生されるWnt3は、RhoAシグナルを活性化し、VLA6依存性CAM-DRを惹起する

小船雅義, 河野豊, 村瀬和幸, 井山諭, 佐藤勉, 瀧本理修, 松永卓也, 加藤淳二, 新津洋司郎

日本癌治療学会誌 ( (一社)日本癌治療学会 ) 42 ( 2 ) 482 - 482 2007年09月 [査読有り]

肝動注療法および全身化学療法にて切除可能となった大腸癌肝転移の1例

佐川保, 佐藤康史, 高山哲治, 平川昌宏, 阿部清一郎, 井山諭, 宮西浩嗣, 河野豊, 高田弘一, 中村とき子, 加藤淳二, 新津洋司郎

癌と化学療法 ( (株)癌と化学療法社 ) 34 ( 9 ) 1481 - 1484 2007年09月 [査読有り]

症例は70歳、男性。横行結腸癌、多発性肝転移と診断した。原発巣による狭窄症状があったことより、横行結腸切除術を施行。肝転移に対しては肝動注、全身化学療法FOLFOX4を施行した。肝転移は縮小し単発となったので13ヵ月後に手術可能となり、肝切除術を施行した。肝動注、全身化学療法により切除可能となった横行結腸癌、多発性肝転移症例を経験したので報告する。(著者抄録)

Wnt3/RhoA/ROCKシグナル伝達は多発性骨髄腫の接着介在性薬物耐性へと自己分泌性に関与する(Wnt3/RhoA/ROCK signaling is involved in adhesion-mediated drug resistance of multiple myeloma in an autocline manner)

小船雅義, 井山諭, 佐藤勉, 瀧本理修, 松永卓也, 河野豊, 村瀬和幸, 加藤淳二, 新津洋司郎

日本癌学会総会記事 ( 日本癌学会 ) 66回 334 - 334 2007年08月 [査読有り]

[Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].

Naoko Araki, Rishu Takimoto, Hiroki Chiba, Hironobu Araki, Tsutomu Sato, Satoshi Iyama, Masahiro Hirakawa, Kaoru Ono, Yutaka Kawano, Koichi Takada, Koji Miyanishi, Masayoshi Kobune, Takuya Matsunaga, Junji Kato, Tokiko Nakamura, Yoshiro Niitsu

[Rinsho ketsueki] The Japanese journal of clinical hematology ( 7 ) 48 ( 7 ) 554 - 8 2007年07月 [査読有り] [国内誌]

A 47-year-old woman was admitted to our hospital in December 1994 with polycythemia. The patient's red blood cell volume was 33 ml/kg and bone marrow cytology was able to rule out other myeloproliferative diseases such as chronic myelogenous leukemia, essential thrombocytosis and myelofibrosis. The patient was diagnosed as having polycythemia vera. She had undergone only phlebotomy until 1999 when the thrombocytosis appeared, subsequent to which she was treated with oral hydroxyurea. However, in March 2006, she developed upper abdominal pain and was admitted to our hospital on March 14th, 2006. Computed tomography scan revealed thromboses in the portal and superior mesenteric veins. Anticoagulation therapy delivered intravenously via the superior mesenteric vein dramatically improved her symptoms and liver function. She is currently on anticoagulation therapy in our outpatient clinic.

DOI PubMed

[Factor XI deficiency caused by a mutation of Gly400Val].

Sato T, Iyama S, Araki N, Murase K, Sato Y, Kobune M, Takimoto R, Matsunaga T, Kato J, Kuroda H, Niitsu Y

[Rinsho ketsueki] The Japanese journal of clinical hematology ( 2 ) 48 ( 2 ) 148 - 150 2007年02月 [査読有り]

DOI PubMed CiNii

[Gastric relapse of stage I ocular adnexal mucosa-associated lymphoid tissue lymphoma].

Sato T, Takimoto R, Iyama S, Ono K, Tanaka S, Araki N, Nishiie K, Murase K, Sato Y, Kobune M, Matsunaga T, Kato J, Niitsu Y

[Rinsho ketsueki] The Japanese journal of clinical hematology ( 1 ) 48 ( 1 ) 56 - 60 2007年01月 [査読有り]

症例は57歳，男性。右涙腺に原発するmucosa-associated lymphoid tissue lymphoma (MALT lymphoma)に対し，局所への放射線照射が施行された。その際の胃内視鏡検査では胃粘膜に軽度の炎症性変化が指摘され，ウレアーゼテストが陽性であったため，ピロリ菌の除菌療法が施行された。その2年後，再び胃内視鏡検査を施行したところ，MALTリンパ腫病変が検出された。涙腺病変と胃病変のIgH遺伝子をサザン法で検索したところ，全く同一の再構成パターンが得られた。このため，ピロリ菌感染による慢性炎症を母地とした異所性発癌ではなく，原発巣の胃転移と考えた。また，涙腺MALTリンパ腫のリンパ腫細胞は，リンパ球が消化管粘膜へ接着する際に必須であるintegrin α4β7を高発現していたため，この接着分子が胃転移に重要な働きをした可能性があると考えられた。

DOI PubMed CiNii

Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis

Yasushi Sato, Tetsuji Takayama, Tomomi Nikaido, Yuko Wada, Tamotsu Sagawa, Seiichiro Abe, Tsutomu Sato, Satoshi Iyama, Kazuyuki Murase, Hironobu Araki, Yasuhiro Sato, Junji Kato, Yoshiro Niitsu, Hideki Chiba

Japanese Journal of Gastroenterology ( 9 ) 104 ( 9 ) 1365 - 1370 2007年 [査読有り]

Amyotrophic lateral sclerosis (ALS) is a degenerative disease involving both upper and lower motor neurons and the pathogenesis of this disorder is still unknown. To date, few reports have suggested that motor neuron diseases may have a paraneoplastic origin. However, it is still under discussion whether ALS occurring in cancer patients is paraneoplastic. A 60-year-old man with rectal cancer (Stage IV) having multiple lung, liver and para-aortic lymph node metastases underwent anterior resection of the rectum as palliative surgery. He was referred to our hospital for adjuvant chemotherapy. Lung and lymph node metastases decreased after 2 courses of chemotherapy using CPT-11 and 5-FU/LV but liver metastases were enlarged, following up increase in CEA. Thereafter, he suffered from muscle weakness in hands, arms, and legs and results of neurophysiologic studies were compatible with primary lateral sclerosis (ALS). For second line chemotherapy, he was treated with low-dose CDDP/5-FU over 6 courses. As a result, the size the of metastatic lesions markedly reduced and CEA was decreased to the normal level. Although significant tumor reduction was observed, his neurological symptoms rapidly progressed. He died of aspiration pneumonia 8 months after onset of the disease. Autopsy revealed that his neuropathological findings were compatible with ALS, and it was thought to be the primary cause of death in the because of absence of cancer progression. In this case the neurological syndrome was not affected by cancer therapy. Thus our case does not support the hypothesis that ALS in associated with cancer and the relationship between both disorders remains uncertain.

DOI PubMed

Ex vivo large-scale generation of human platelets from cord blood CD34(+) cells

Takuya Matsunaga, Ikuta Tanaka, Masayoshi Kobune, Yutaka Kawano, Maki Tanaka, Kageaki Kuribayashi, Satoshi Iyama, Tsutomu Sato, Yasushi Sato, Rishu Takimoto, Tetsuji Takayama, Junji Kato, Takafumi Ninomiya, Hirofumi Hamada, Yoshiro Niitsu

STEM CELLS ( ALPHAMED PRESS ) 24 ( 12 ) 2877 - 2887 2006年12月 [査読有り]

In the present investigation, we generated platelets (PLTs) from cord blood ( CB) CD34(+) cells using a three- phase culture system. We first cultured 500 CB CD34(+) cells on telomerase gene- transduced human stromal cells ( hTERT stroma) in serum-free medium supplemented with stem cell factor ( SCF), Flt-3/ Flk-2 ligand ( FL), and thrombopoietin ( TPO) for 14 days. We then transferred the cells to hTERT stroma and cultured for another 14 days with fresh medium containing interleukin-11 (IL- 11) in addition to the original cytokine cocktail. Subsequently, we cultured the cells in a liquid culture medium containing SCF, FL, TPO, and IL- 11 for another 5 days to recover PLT fractions from the supernatant, which were then gel- filtered to purify the PLTs. The calculated yield of PLTs from 1.0 unit of CB ( 5 x 106 CD34(+) cells) was 1.26 x 10(11) - 1.68 x 10(11) PLTs. These numbers of PLTs are equivalent to 2.5 - 3.4 units of random donorderived PLTs or 2/ 5 - 6/ 10 of single- apheresis PLTs. The CB- derived PLTs exhibited features quite similar to those from peripheral blood in morphology, as revealed by electron micrographs, and in function, as revealed by fibrinogen/ ADP aggregation, with the appearance of beta-selectin and activated glycoprotein IIb- IIIa antigens. Thus, this culture system may be applicable for large- scale generation of PLTs for future clinical use.

DOI PubMed

[Peripheral T-cell lymphoma presenting with eosinophilia due to interleukin-5 produced by lymphoma cells].

Matsunaga T, Sato T, Iyama S, Tanaka S, Murase K, Sato Y, Kobune M, Takimoto R, Kato J, Kuroda H, Niitsu Y

[Rinsho ketsueki] The Japanese journal of clinical hematology ( 11 ) 47 ( 11 ) 1457 - 1462 2006年11月 [査読有り]

症例は72歳, 男性。頸部リンパ節腫脹の精査を目的に入院し, リンパ節生検の結果から, 末梢性T細胞性リンパ腫 (peripheral T cell lymphoma; PTCL) と診断した。著明な好酸球増多を認めたため, 血清Interleukin-5 (IL-5) を測定したところ高値を示した。また, 生検したリンパ節組織の免疫染色ではIL-5陽性の細胞が散見された。CHOP療法を2クール施行したところ, 腫大したリンパ節は消失し, 好酸球数は正常となった。また, これにともない血清IL-5も正常化した。PTCLでは稀に好酸球増多を合併すると報告されているが, 本症例では腫瘍細胞由来のIL-5が原因と推測された。

DOI PubMed CiNii

A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer

Yasushi Sato, Tetsuji Takayama, Tamotsu Sagawa, Tetsuro Okamoto, Koji Miyanishi, Tsutomu Sato, Hironobu Araki, Satoshi Iyama, Seiichiro Abe, Kazuyuki Murase, Rishu Takimoto, Hisayasu Nagakura, Masato Hareyama, Junji Kato, Yoshiro Niitsu

CANCER CHEMOTHERAPY AND PHARMACOLOGY ( SPRINGER ) 58 ( 5 ) 570 - 576 2006年11月 [査読有り]

Purpose: To determine the recommended dose (RD) of cis-diammine-glycolatoplatinum (nedaplatin) when given concurrently with 5-FU and high dose radiation therapy in the treatment of esophageal cancer. The purpose of the phase II trial is to determine efficacy and further define the side effect profile. Methods: Twenty-six patients with clinical stage I to IVA squamous cell carcinoma of the esophagus were enrolled in a non-surgical treatment comprised of a fixed dose of fluorouracil (400 mg/m(2) administered as continuous intravenous infusion on days 1-5 and days 8-12) plus escalating doses of nedaplatin (40 mg/m(2) in level 1, 50 mg/m(2) in level 2, or 60 mg/m(2) in level 3 on days 1 and 8), repeated twice every 3 weeks with concurrent radiotherapy (60 Gy). Results: Between July 1998 and February 2004, a total of 26 patients entered this trial, all of whom were considered evaluable for toxicity assessment. In phase I of the study, 12 patients were treated in sequential cohorts of three to six patients per dose level. The maximum tolerated dose was reached at level 3 with two grade 4 neutropenia and one grade 4 thrombocytopenia. Thus, the recommended dosing schedule is level 2. Of the 20 patients treated at the RD level 2, including 6 patients of the RD phase I portion, 8 out of 20 patients (40%) had grade 3-4 neutropenia, 5 patients (25.0%) had grade 3-4 thrombocytopenia, 4 patients (20.0%) had grade 3 anemia and 4 patients (20.0%) had grade 3-4 esophagitis. Other toxicities were relatively mild and usually of grade 2 or less. Objective responses were noted in the 26 patients (overall response rate, 88.5%) including 11 (42.3%) complete remissions. The 1- and 3-year survival rates were 65.1 and 37.2%, respectively, with a median survival time of 21.2 months. Conclusions: The combination of nedaplatin and 5-FU with radiation is a feasible regimen that shows promising antitumor activity with an acceptable safety profile in patients with esophageal cancer.

DOI PubMed

A case of recurrent biliary cystadenocarcinoma successfully treated with 5FU/CDDP systemic chemotherapy

Satoshi Iyama, Yasuo Takahashi, Naoaki Shintani, Koshi Fujikawa, Syunichi Ohkubo, Yasushi Sato, Tsutomu Sato, Yasuhiro Sato, Keisuke Ohnuma, Yoshiro Niitsu

Japanese Journal of Gastroenterology ( 10 ) 103 ( 10 ) 1163 - 1168 2006年10月 [査読有り]

We report a case of biliary cystadenocarcinoma which recurred 41 months postoperatively. A 60-year-old woman was admitted for further examination of multiple metastatic tumors and a large amount of ascites. Systemic administration of 5FU and CDDP caused her CEA level to decrease gradually and abdominal computed tomography revealed considerable reduction of the metastatic tumors and ascites. Since her general condition had improved, chemotherapy was continued in the outpatient clinic.

DOI PubMed

ヒトTERT-stroma細胞を用いた末梢血CD133陽性細胞のex vivo増幅系の確立

小船雅義, 河野豊, 千葉大樹, 井山諭, 佐藤勉, 瀧本理修, 松永卓也, 加藤淳二, 濱田洋文, 新津洋司郎

臨床血液 ( (一社)日本血液学会-東京事務局 ) 47 ( 9 ) 1151 - 1151 2006年09月 [査読有り]

[De novo CD5-positive diffuse large B-cell lymphoma associated with autoimmune hemolytic anemia presenting as erythroid hypoplasia].

Kuroda H, Matsunaga T, Iyama S, Takimoto R, Shirao S, Kida M, Watanabe H, Konuma Y, Hirayama Y, Kohda K, Niitsu Y

[Rinsho ketsueki] The Japanese journal of clinical hematology ( 7 ) 47 ( 7 ) 633 - 638 2006年07月 [査読有り]

DOI PubMed CiNii

Amelioration of murine dextran sulfate sodium-induced colitis by ex vivo extracellular superoxide dismutase gene transfer

Takatomi Oku, Satoshi Iyama, Tsutomu Sato, Yasushi Sato, Maki Tanaka, Tamotsu Sagawa, Kageaki Kuribayashi, Tetsuya Sumiyoshi, Kazuyuki Murase, Takuro Machida, Tetsuro Okamoto, Takuya Matsunaga, Tetsuji Takayama, Minoru Takahashi, Junji Kato, Hirofumi Hamada, Yoshiro Niitsu

INFLAMMATORY BOWEL DISEASES ( LIPPINCOTT WILLIAMS & WILKINS ) 12 ( 7 ) 630 - 640 2006年07月 [査読有り]

Background: Although the etiology of inflammatory bowel disease has not been fully clarified, reactive oxygen species is speculated to be involved. Extracellular superoxide dismutase (EC-SOD), an isozyme of SODs, is known to function mainly in body fluids. We investigated the efficacy of an ex vivo EC-SOD gene transfer into dextran sulfate sodium (DSS)-induced colitis mice. Materials and Methods: Experimental colitis was induced by providing Balb/c mice with DSS in sterile distilled water provided as desired. The syngenic fibroblasts were obtained from Balb/c mice embryos and retrovirally transduced with the hEC-SOD gene. These engineered cells were confirmed to secrete EC-SOD in culture medium by enzyme-linked immunosorbent assay and were inoculated subcutaneously in the backs of DSS-treated mice. Mucosal injury of the colon was evaluated by the disease activity index (DAI: body weight, rectal bleeding, and stool consistency), grading of histologic disease severity, and levels of cytokine (tumor necrosis factor-alpha, interieukin-1 beta) production. 8-Hydroxydeoxyguanosine (8-OHdG) levels in the mucosal tissue were assessed by immunohistochemical staining. Malondialdehyde (MDA) was measured using a colorimetric assay. Results: A significant improvement was observed in DAI score and histologic severity as well as in mucosal tissue levels of inflammatory cyrokines, 8-OHdG, and MDA of mice treated with the EC-SOD gene as compared with those without gene therapy, not only in a mild colitis model but also in a severe colitis model. Survival of treated mice in these models was significantly prolonged. Conclusions: Ex vivo transfer of the EC-SOD gene was feasible for treatment of DSS-induced colitis.

DOI PubMed

　前のページ - 次のページ　

<井山 諭>

論文 - 井山 諭

<井山　諭>

論文 - 井山　諭